Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Squamous Cell Carcinoma does not have ...

Some genes are known to drive cancer, and astonishing new research shows why: Mutations in the noncoding regions become functional, altering the abundance of messenger RNA, or mRNA, and ...

Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell ...

Nanozyme Medical Center, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China Nanozyme Laboratory in Zhongyuan, Henan Academy of Innovations in Medical Science, Zhengzhou, ...

No writing assistance was utilized in the production of this manuscript. Ocular surface squamous neoplasia is the most common nonpigmented ocular surface lesion. Ocular surface squamous neoplasia ...

WHIM-like syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis) developed in a patient with gain of CXCR4 function. Plerixafor, a CXCR4 antagonist, led to symptom reduction.

Esophageal squamous cell carcinoma (ESCC) accounts for around 90% of esophageal cancers, especially in East Asia. New findings in The American Journal of Pathology, published by Elsevier ...

Stage 3B non-small cell lung cancer (NSCLC), along with stage 3C and stage 4 NSCLC, are considered advanced lung cancer. In general, when cancer reaches this point, it's treatable but not considered ...

5 State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Objectives Oesophageal ...

Oral cavity squamous cell carcinoma (OCSCC), the most common subtype of head and neck cancer, is a devastating disease, causing substantial morbidity and mortality. Only a handful of targeted ...